To print: Select File and then Print from your browser's menu

Title: FDA Approves Valproate for Bipolar Disorder, Seizures, and Migraine Headaches

"FDA Approves Valproate for Bipolar Disorder, Seizures, and Migraine Headaches"

NEW YORK -- July 30, 2008 -- The US Food and Drug Administration (FDA) has approved valproic acid (Stavzor) delayed-release capsules in 125-, 250-, and 500-mg strengths. "The small size and soft gel capsule formulation of valproate should make this new product easy to swallow, which in my experience is critical to helping valproate patients start, and stay on, their medication," said Miguel Martelli, MD, a psychiatrist in private practice in Saint Marys, Georgia. Valproate products should not be administered to patients with hepatic disease or significant hepatic dysfunction. In a clinical trial of valproate in elderly patients with dementia, some patients experienced somnolence, sometimes requiring discontinuation. Cases of life-threatening pancreatitis, some rapidly progressing to death, have been reported in both adults and children receiving valproate. Valproate is contraindicated in patients with known urea cycle disorders. Administration of valproic acid and topiramate has been associated with hyperammonaemia, with and without encephalopathy. Common adverse events (>5% incidence) associated with valproate in clinical studies were nausea, somnolence, dizziness, vomiting, asthenia, abdominal pain, dyspepsia, rash, diarrhoea, increased appetite, tremour, weight gain, back pain, alopecia, headache, fever, anorexia, constipation, diplopia, amblyopia/blurred vision, ataxia, nystagmus, emotional lability, thinking abnormal, amnesia, flu syndrome, infection, bronchitis, rhinitis, thrombocytopenia, ecchymosis, peripheral oedema, insomnia, nervousness, depression, pharyngitis, dyspnea, and tinnitus. SOURCE: Noven Therapeutics, LLC

Copyright © 2009 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content.